CTMX - Company ID 0001501989
The table below shows CytomX Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $1.42M | $10.26M | $5.96M | $18.66M | $50.92M | $33.43M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $17.60M | $19.24M | $15.30M | $13.32M | $18.87M | $21.37M |
CytomX Therapeutics, Inc. reported annual revenue of $76.20M for fiscal year 2025. That is down 44.8% from $138.10M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $15.04M (FY 2016) to $76.20M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $7.60M |
| $10.69M |
| $6.43M |
| $6.62M |
| $9.43M |
| $7.95M |
| Operating income | -$23.78M | -$19.67M | -$15.77M | -$1.29M | $22.62M | $4.11M |
| Income tax | $60.00K | $59.00K | $58.00K | $63.00K | $62.00K | $61.00K |
| Net income | -$20.67M | -$18.25M | -$14.23M | -$154.00K | $23.52M | $5.74M |
| EPS (diluted) | - | - | - | - | - | - |